WW
WW International, Inc. · Consumer Cyclical
11.62
3.25%(-0.39)
Close11.94
2.75%(+0.32)
After HoursLast Updated: — ET
52W L: $10.7952W H: $46.95
$11.66
CHG-9.99 (-46.14%)
H$25.04
L$10.83
VOL5.8M
WW (1h)
WW International, Inc. · Consumer Cyclical
New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation
Office of the CEO Established to Oversee Business Operations Board Forms Transition Committee and Commences CEO Search NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced leadership and governance changes, including the establishment of an Office of the CEO and the formation of a new Transition Committee of the Board of Directors (“the Board”). These actions follow Tara Comonte's departure from the Company, effective March 31, 2026.
Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers' integrated care platform
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
WW International (NASDAQ:WW), the global weight management company formerly known as Weight Watchers, released its fourth quarter and full-year 2025 financial results, showing stronger-than-expected earnings despite a year-over-year decline in total revenue. The company's shares surged more than 12% following the report, trading just shy of $24 on Monday morning.
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with continued growth in first quarter 2026 Fourth Quarter Total Revenue of $163 million; Clinical Subscription Revenue of $27 million, up 32% year-over-year Fourth Quarter Net Loss of $6 million; Net Loss Margin of 3.6%; Adjusted EBITDA 1 of $18 million and Adjusted EBITDA Margin 1 of 11.1% Provides First Quarter 2026 End of Period Subscriber Estimates and Full Year 2026 Financial Guidance NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the fourth quarter and full year fiscal 2025 ended December 31, 2025 2 in this Earnings Press Release and a Shareholder Letter posted on the Company's Corporate Website . “Our industry is undergoing a profound transformation driven by GLP-1 medications, and Weight Watchers is evolving alongside it,” said Tara Comonte, CEO of Weight Watchers.
Hawks Carney
director
1,166 SH @ $0.00
2026-01-02
Bornstein Julie
director
1,166 SH @ $0.00
2026-01-02
O'Connor-Brooks Fallon Julia
director
1,166 SH @ $0.00
2026-01-02
Sjoqvist Nikolaj H
director
1,166 SH @ $0.00
2026-01-02
Mason Michael B
director
1,166 SH @ $0.00
2026-01-02
DAVIS EUGENE I
director
1,166 SH @ $0.00
2026-01-02
Bornstein Julie
director
1,219 SH @ $0.00
2025-12-19
DAVIS EUGENE I
director
1,219 SH @ $0.00
2025-12-19